Bionano Genomics, Inc.
BNGO
$1.18
-$0.02-1.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.36% | 3.56% | -2.60% | 21.31% | -13.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.36% | 3.56% | -2.60% | 21.31% | -13.36% |
| Cost of Revenue | 18.46% | -2.39% | -4.09% | -72.47% | -37.22% |
| Gross Profit | 24.07% | 10.69% | -0.53% | 139.90% | 34.51% |
| SG&A Expenses | 2.37% | -11.33% | -25.88% | -4.23% | -27.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.89% | -2.27% | -17.42% | -44.58% | -38.35% |
| Operating Income | 7.46% | 6.71% | 27.68% | 62.27% | 50.64% |
| Income Before Tax | -8.31% | -167.95% | 60.75% | 80.80% | 57.73% |
| Income Tax Expenses | -30.00% | 42.86% | 3,400.00% | -41.67% | -61.54% |
| Earnings from Continuing Operations | -8.25% | -167.67% | 60.58% | 80.78% | 57.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.25% | -167.67% | 60.58% | 80.78% | 57.74% |
| EBIT | 7.46% | 6.71% | 27.68% | 62.27% | 50.64% |
| EBITDA | 9.28% | 7.42% | 33.54% | 63.94% | 57.94% |
| EPS Basic | 67.74% | 34.31% | 93.70% | 94.85% | 86.17% |
| Normalized Basic EPS | 67.72% | 34.25% | 90.01% | 90.08% | 88.18% |
| EPS Diluted | 67.74% | 34.31% | 93.70% | 94.85% | 86.17% |
| Normalized Diluted EPS | 67.72% | 34.25% | 90.01% | 90.08% | 88.18% |
| Average Basic Shares Outstanding | 235.54% | 307.54% | 525.33% | 273.03% | 205.60% |
| Average Diluted Shares Outstanding | 235.54% | 307.54% | 525.33% | 273.03% | 205.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |